Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 0.47 |
| ▸ | SMO | Q99835 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 8/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | PGR | P06401 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL413216 | 0.83 | CYP11B2 (0.69) | CYP11B2SMONR3C1CYP11B1MAPK1 | |
| SCHEMBL836802 | 0.82 | NPC1 (0.48) | CYP11B2SMONR3C1CYP11B1PGR | |
| SCHEMBL443024 | 0.82 | NR3C1 (0.62) | CYP11B2SMONR3C1PGR | |
| SCHEMBL25269630 | 0.80 | CYP11B2 (0.47) | CYP11B2SMONR3C1CYP11B1MAPK1 | |
| SCHEMBL835119 | 0.78 | NR3C1 (0.44) | SMONR3C1PGR | |
| SCHEMBL27765911 | 0.78 | CYP11B1 (0.52) | CYP11B2SMONR3C1CYP11B1MAPK1 | |
| SCHEMBL28782071 | 0.78 | NR3C1 (0.42) | SMONR3C1PGR | |
| SCHEMBL836441 | 0.77 | PLA2G10 (0.53) | CYP11B2SMONR3C1CYP11B1PGR | |
| SCHEMBL838318 | 0.77 | SMO (0.44) | CYP11B2SMONR3C1PGR | |
| SCHEMBL20180252 | 0.76 | SMO (0.59) | CYP11B2SMOMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331034-B2 | Substituted pyrrolidine amides V | GRUENENTHAL GMBH (DE) | 2025-06-17 | — | — | US | disclosed |
| EP-3986886-A2 | SUBSTITUTED PYRROLIDINE AMIDES V | Grünenthal GmbH (DE) | 2022-04-27 | — | — | EP | disclosed |
| US-20220106294-A1 | SUBSTITUTED PYRROLIDINE AMIDES V | GRUENENTHAL GMBH (DE) | 2022-04-07 | — | — | US | disclosed |
| US-20220106294-A1 | SUBSTITUTED PYRROLIDINE AMIDES V | GRUENENTHAL GMBH (DE) | 2022-04-07 | — | — | US | disclosed |
| WO-2020254552-A2 | SUBSTITUTED PYRROLIDINE AMIDES V | Grünenthal GmbH (DE) | 2020-12-24 | — | — | WO | disclosed |
| US-20120252770-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| CN-101611015-B | Indazolyl ester and indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders | ASTRAZENECA AB SE | 2012-09-26 | — | — | CN | disclosed |
| EP-2102169-B1 | INDAZOLYL AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2012-06-20 | — | — | EP | disclosed |
| US-8143290-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20110071194-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20100197644-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-05 | — | — | US | disclosed |
| US-7728030-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2010-06-01 | — | — | US | disclosed |
| CN-101611015-A | Indazolyl ester and indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | CN | disclosed |
| EP-2102169-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | AstraZeneca AB (SE) | 2009-09-23 | — | — | EP | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| WO-2008076048-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214641-A1 | Chemical compounds 572 | ABCG2, ABCB1, CYP11B2 | CYP11B2 3/4885SMO 2829/4885NR3C1 2841/4885 |
| US-20220106294-A1 | SUBSTITUTED PYRROLIDINE AMIDES V | NR3C1, NR3C2, MC2R | CYP11B2 21/4885SMO 4698/4885NR3C1 1/4885 |
| US-20100197644-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | CYP11B2 3/4885SMO 2829/4885NR3C1 2841/4885 |
| US-12331034-B2 | Substituted pyrrolidine amides V | NR3C1, NR3C2, MC2R | CYP11B2 21/4885SMO 4698/4885NR3C1 1/4885 |
| US-20120252770-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | CYP11B2 3/4885SMO 2829/4885NR3C1 2841/4885 |
| US-20110071194-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | CYP11B2 3/4885SMO 2829/4885NR3C1 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.